It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
It is well established that the apolipoprotein epsilon 4 allele (APOE4) and being female are risk factors for late onset Alzheimer’s disease (AD) and declines in verbal learning and memory are early cognitive symptoms of conversion to AD. Because of conflicting findings regarding the effects of statins on cognition, this study examined statin use with respect to verbal learning and memory by APOE4 status in a sample of cognitively unimpaired women at risk for AD. Neuropsychological, statin use, and APOE4 data were utilized as a secondary analysis from an ongoing longitudinal study at the Banner Alzheimer’s Institute in Arizona. Subjects were cognitively unimpaired women aged 47-75 with a family history of probable AD in at least one first-degree relative. Neuropsychological outcome variables included total learning, immediate memory, and delayed memory scores from the Rey Auditory Verbal Learning Test (RAVLT). Statin use was defined by use of a cholesterol lowering drug at study enrollment. APOE4 status was defined by presence of at least one APOE4 allele. Linear regression analyses were conducted to determine existence of interactions between statin use and APOE4 status on cognition. Statistically significant interactions were found between statin use and APOE4 status in RAVLT total learning and immediate memory. Statin use in women APOE4 non-carriers was associated with better verbal learning and immediate memory performances whereas statin use in women APOE4 carriers was associated with worse performances on these same tasks. Conclusions. Findings suggest that sex and APOE4 status may be important factors in consideration of statin use.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Stanford University, School of Medicine, Department of Psychiatry & Behavioral Sciences, Stanford, California, United States
2 Stanford University, School of Medicine, Stanford, California, United States